JP4753088B2 - 抗炎症薬としてのＡＣｈＥアンチセンスデオキシオリゴヌクレオチド - Google Patents

抗炎症薬としてのＡＣｈＥアンチセンスデオキシオリゴヌクレオチド Download PDF

Info

Publication number
JP4753088B2
JP4753088B2 JP2006537550A JP2006537550A JP4753088B2 JP 4753088 B2 JP4753088 B2 JP 4753088B2 JP 2006537550 A JP2006537550 A JP 2006537550A JP 2006537550 A JP2006537550 A JP 2006537550A JP 4753088 B2 JP4753088 B2 JP 4753088B2
Authority
JP
Japan
Prior art keywords
ache
inhibitor
expression
seq
mrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006537550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007509186A5 (enExample
JP2007509186A (ja
Inventor
ヘルモナ ソレク
ラズ イラミヤ
Original Assignee
イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブル ユニバーシティ オブ エルサレム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブル ユニバーシティ オブ エルサレム filed Critical イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブル ユニバーシティ オブ エルサレム
Publication of JP2007509186A publication Critical patent/JP2007509186A/ja
Publication of JP2007509186A5 publication Critical patent/JP2007509186A5/ja
Application granted granted Critical
Publication of JP4753088B2 publication Critical patent/JP4753088B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006537550A 2003-10-26 2004-10-26 抗炎症薬としてのＡＣｈＥアンチセンスデオキシオリゴヌクレオチド Expired - Fee Related JP4753088B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL158600A IL158600A (en) 2003-10-26 2003-10-26 Dioxysoligonucleotide Antisense Against Acetylcholinesterase as an Anti-Inflammatory Agent
IL158600 2003-10-26
PCT/IL2004/000978 WO2005039480A2 (en) 2003-10-26 2004-10-26 AChE ANTISENSE DEOXYOLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT

Publications (3)

Publication Number Publication Date
JP2007509186A JP2007509186A (ja) 2007-04-12
JP2007509186A5 JP2007509186A5 (enExample) 2007-12-06
JP4753088B2 true JP4753088B2 (ja) 2011-08-17

Family

ID=34044237

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006537550A Expired - Fee Related JP4753088B2 (ja) 2003-10-26 2004-10-26 抗炎症薬としてのＡＣｈＥアンチセンスデオキシオリゴヌクレオチド

Country Status (6)

Country Link
US (3) US20060069051A1 (enExample)
EP (2) EP1682072A4 (enExample)
JP (1) JP4753088B2 (enExample)
CA (1) CA2543305A1 (enExample)
IL (1) IL158600A (enExample)
WO (1) WO2005039480A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007399A2 (en) * 2006-04-10 2008-12-31 Ester Neurosciences Ltd. Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases
US20110136897A1 (en) * 2008-08-14 2011-06-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Toll-like receptor 9 agonists for the treatment of anxiety-related disorders and inflammatory disorders
MX2011011517A (es) 2009-04-29 2012-06-19 Amarin Corp Plc Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo.
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20220102008A1 (en) * 2020-09-30 2022-03-31 Genentech, Inc. Methods and systems for placebo response modeling

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999008672A1 (en) * 1997-08-15 1999-02-25 Shire International Licensing Bv Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity
US5891725A (en) * 1992-04-15 1999-04-06 Yissum Research Development Co. Of The Hebrew Univ. Of Jerusalem Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them
JP2001510336A (ja) * 1996-12-12 2001-07-31 イスム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ 大学 オブ エルサレム 合成アンチセンスオリゴデオキシヌクレオチド類およびそれらを含む医薬組成物
WO2003002739A1 (en) * 2001-05-24 2003-01-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495579B1 (en) * 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
EP2007399A2 (en) * 2006-04-10 2008-12-31 Ester Neurosciences Ltd. Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891725A (en) * 1992-04-15 1999-04-06 Yissum Research Development Co. Of The Hebrew Univ. Of Jerusalem Synthetic antisense oligodeoxynucleotides and pharmaceutical compositions containing them
JP2001510336A (ja) * 1996-12-12 2001-07-31 イスム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ 大学 オブ エルサレム 合成アンチセンスオリゴデオキシヌクレオチド類およびそれらを含む医薬組成物
WO1999008672A1 (en) * 1997-08-15 1999-02-25 Shire International Licensing Bv Use of cholinesterase inhibitor for treating diseases associated with proteolytic enzyme activity
WO2003002739A1 (en) * 2001-05-24 2003-01-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antisense oligonucleotide against human acetylcholinesterase (ache) and uses thereof

Also Published As

Publication number Publication date
IL158600A0 (en) 2004-05-12
WO2005039480A3 (en) 2006-08-03
WO2005039480A8 (en) 2006-06-15
EP1682072A4 (en) 2010-10-13
CA2543305A1 (en) 2005-05-06
IL158600A (en) 2015-07-30
US20130310441A1 (en) 2013-11-21
JP2007509186A (ja) 2007-04-12
EP1682072A2 (en) 2006-07-26
US20060069051A1 (en) 2006-03-30
US20090005331A1 (en) 2009-01-01
US8722876B2 (en) 2014-05-13
WO2005039480A2 (en) 2005-05-06
EP2599489A1 (en) 2013-06-05

Similar Documents

Publication Publication Date Title
Zhang et al. DKK3 ameliorates neuropathic pain via inhibiting ASK-1/JNK/p-38-mediated microglia polarization and neuroinflammation
Lu et al. Eosinophil extracellular traps drive asthma progression through neuro-immune signals
Fattori et al. The specialised pro‐resolving lipid mediator maresin 1 reduces inflammatory pain with a long‐lasting analgesic effect
Mietto et al. Neurotrauma and inflammation: CNS and PNS responses
Lv et al. Integrated multi-omics reveals the activated retinal microglia with intracellular metabolic reprogramming contributes to inflammation in STZ-induced early diabetic retinopathy
JP4316373B2 (ja) ヒトのアセチルコリンエステラーゼ（ａｃｈｅ）に対するアンチセンスオリゴヌクレオチド及びその使用
US8722876B2 (en) Antisense oligonucleotides against AChE in the treatment of gastrointestinal inflammation disorders
Connelly et al. Pertussis toxin exacerbates and prolongs airway inflammatory responses during Bordetella pertussis infection
Liu et al. Neuroprotection and its molecular mechanism following spinal cord injury☆
Xiang et al. The lncRNA Ftx/miR-382-5p/Nrg1 axis improves the inflammation response of microglia and spinal cord injury repair
Geng et al. Electroacupuncture in the repair of spinal cord injury: inhibiting the Notch signaling pathway and promoting neural stem cell proliferation
Lim et al. Presence and activation of pro-inflammatory macrophages are associated with CRYAB expression in vitro and after peripheral nerve injury
Lu et al. miR-204 ameliorates osteoarthritis pain by inhibiting SP1-LRP1 signaling and blocking neuro-cartilage interaction
Chen et al. A novel peptide ADAM8 inhibitor attenuates bronchial hyperresponsiveness and Th2 cytokine mediated inflammation of murine asthmatic models
Tuxworth et al. Attenuating the DNA damage response to double-strand breaks restores function in models of CNS neurodegeneration
US9927437B2 (en) Treating neurodegenerative disease
Mitra et al. Hypertonic saline attenuates the cytokine-induced pro-inflammatory signature in primary human lung epithelia
RU2663100C2 (ru) Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний
Feng et al. Inhibition of IFITM3 in cerebrovascular endothelium alleviates Alzheimer's‐related phenotypes
CN115006534B (zh) 钾离子通道Kir4.1抑制剂治疗抑郁症的用途和药物组合物
JP4427639B2 (ja) 合成アンチセンスオリゴデオキシヌクレオチド類およびそれらを含む医薬組成物
Bruno Current insights into the pathogenesis of acute and chronic pancreatitis
US20130018081A1 (en) AChE ANTISENSE OLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT
Yasukochi et al. The Circadian Clock Component REV-ERB Is an Analgesic Target for Cancer-Induced Tactile Pain Hypersensitivity
JP5784754B2 (ja) 神経疾患の予防または処置のためのｉｃａｍ−１の使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100921

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101217

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110118

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110511

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140603

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees